Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine-Cisplatin Neoadjuvant Therapy in Early Stage NSCLC
NCT00191126Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2000
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of gemcitabine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Progression Free Survival. Started Sep 2000; status: completed.
02
Drugs
gemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00191126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191126.